Collagenase Effective for Recurrent Dupuytren
Collagenase treatment improves contracture recurrence in patients after prior surgery
By
Alun Evans
March 11, 2026
Clinical Scorecard: Collagenase Effective for Recurrent Dupuytren
At a Glance
Category Detail
Condition Recurrent Dupuytren contracture Key Mechanisms Injection therapy with collagenase clostridium histolyticum (CCH) Target Population Patients with recurrence of Dupuytren contracture after prior surgery Care Setting Multicenter clinical settings in the US
Key Highlights
CCH injections provide a nonsurgical treatment option for recurrent Dupuytren contracture. Clinical success achieved in 65% of treated joints at first evaluation. Average improvement in joint extension of 38° within 12 months post-treatment. Safety profile consistent with previous reports; skin tears most common complication. Surgical retreatment carries higher complication risks compared to CCH therapy. Guideline-Based Recommendations
Diagnosis
Define recurrence as a functionally considerable increase in flexion contracture of at least 20°. Management
Consider collagenase clostridium histolyticum injections for patients with recurrent Dupuytren contracture. Monitoring & Follow-up
Evaluate joint extension improvements at 1 month and within 12 months post-treatment. Risks
Monitor for treatment-related adverse events, including skin tears and tendon ruptures. Patient & Prescribing Data
101 patients with recurrent Dupuytren contracture, mean age 64 years.
CCH treatment is effective and well tolerated, with outcomes comparable to primary treatment.
Clinical Best Practices
Assess the severity of contracture and joint involvement before treatment. Educate patients on the risks of repeat surgery versus CCH therapy. Monitor for adverse events post-injection and provide appropriate follow-up care. References
